Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | F10 | P00742 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4882290 | 0.96 | F10 (0.43) | RAB9AF10MAPTSMN1; SMN2MEN1 | |
| SCHEMBL5237942 | 0.85 | F10 (0.36) | RAB9AF10MAPTSMN1; SMN2MEN1 | |
| SCHEMBL8244509 | 0.81 | F10 (0.52) | RAB9AF10MAPTSMN1; SMN2MEN1 | |
| SCHEMBL8247423 | 0.81 | LMNA (0.42) | RAB9AF10MAPTSMN1; SMN2POLB | |
| SCHEMBL3621342 | 0.79 | F10 (0.51) | RAB9AF10MAPTSMN1; SMN2MEN1 | |
| SCHEMBL8243190 | 0.78 | F10 (0.48) | F10MAPTSMN1; SMN2KMT2APOLB | |
| SCHEMBL3621990 | 0.78 | LMNA (0.40) | RAB9AF10MAPTSMN1; SMN2POLB | |
| SCHEMBL13545926 | 0.78 | MAPT (0.53) | MAPTSMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL5231653 | 0.77 | MAPT (0.56) | MAPTSMN1; SMN2MEN1KMT2AATM | |
| SCHEMBL4878211 | 0.77 | F10 (0.47) | RAB9AF10SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214533-A1 | Cyclic Iminocarbamates And Their Use | BAYER HEALTHCARE AG (DE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214533-A1 | Cyclic Iminocarbamates And Their Use | BAYER HEALTHCARE AG (DE) | 2008-09-04 | — | — | US | disclosed |
| WO-2006058630-A1 | CYCLIC IMINOCARBAMATES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214533-A1 | Cyclic Iminocarbamates And Their Use | F2, UQCRB, F12 | RAB9A 2655/4885F10 26/4885MAPT 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.